UNSPSC 51391812: Pholedrine sulfate

This classification denotes an adrenergic agent with the molecular formula 2C10H15NO.CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WB6LNL73BR, chemically known as propane, 1-(p-hydroxyphenyl)-2-methylamino-, sulfate but more generally known as pholedrine sulfate, which bears US NIH Compound Identifier 93020. European Medicines Agency schedules Pholedrine sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03790MIG.

Most nations, for tariff and trade purposes, schedule pholedrine sulfate under HS 29222900 and SITC 51462. As of Q4 2014, PHOLEDRINE SULFATE remains US FDA's Preferred Term for this commodity. SMILES: CC(CC1CCC(CC1)O)NC.CC(CC1CCC(CC1)O)NC.OS(=O)(=O)O.

UNSPSC 51391812 Pholedrine sulfate is a Commodity code that captures pharmaceutical products and related drug-delivery systems procured by state and local health authorities. Based on recent solicitations, state and local governments are buying naloxone (an opioid antagonist) and safe drug deactivation systems through this code to support community health and substance-abuse-response initiatives. The issuing bodies are primarily county health departments and state health agencies — Seminole County, Florida and the Texas Health and Human Services Commission have both posted activity under this code within the past quarter. Procurement occurs through both traditional competitive bidding (IFB) and exploratory market-intelligence gathering (RFI) mechanisms as these jurisdictions evaluate their pharmacy supply chains and emergency-response capabilities.

Geographically, recent activity is concentrated in Florida and Texas. Seminole County issued IFB 60459723LAS on June 30, 2026, to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, with a response deadline of July 26, 2026. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, seeking vendor capabilities for direct-to-manufacturer prescription programs that could streamline pharmaceutical procurement outside traditional pharmacy benefit manager and group purchasing organization channels. Neither opportunity specifies explicit set-asides for disadvantaged enterprises, though the Seminole County IFB requires drug-free workplace certification, E-Verify compliance, and carries a three-month probationary termination clause; the Texas RFI operates as preliminary due diligence before formal competitive solicitation.